JP2011529912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529912A5 JP2011529912A5 JP2011521353A JP2011521353A JP2011529912A5 JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5 JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- lipid
- cholesterol
- nanoparticle
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 claims 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 15
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- 235000012000 cholesterol Nutrition 0.000 claims 11
- 150000002632 lipids Chemical class 0.000 claims 10
- -1 cationic lipid Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 125000002091 cationic group Chemical group 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229940106189 ceramide Drugs 0.000 claims 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 3
- 230000000799 fusogenic effect Effects 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 230000004647 pro-inflammatory pathway Effects 0.000 claims 1
- 230000006482 proangiogenic pathway Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CC(*)(*)C(*)(*CCC1)C1(*)N(*)CCC* Chemical compound CC(*)(*)C(*)(*CCC1)C1(*)N(*)CCC* 0.000 description 5
- MZQUWCQHUCBQSW-UHFFFAOYSA-N IN1C(CCC2)N2CCC1 Chemical compound IN1C(CCC2)N2CCC1 MZQUWCQHUCBQSW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8528908P | 2008-07-31 | 2008-07-31 | |
| US61/085,289 | 2008-07-31 | ||
| PCT/US2009/052396 WO2010014895A2 (en) | 2008-07-31 | 2009-07-31 | Nanoparticle compositions for nucleic acids delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529912A JP2011529912A (ja) | 2011-12-15 |
| JP2011529912A5 true JP2011529912A5 (enExample) | 2012-07-26 |
Family
ID=41610973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521353A Pending JP2011529912A (ja) | 2008-07-31 | 2009-07-31 | 核酸送達システム用のナノ粒子組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110111044A1 (enExample) |
| EP (1) | EP2304026A4 (enExample) |
| JP (1) | JP2011529912A (enExample) |
| CA (1) | CA2731173A1 (enExample) |
| TW (1) | TW201004658A (enExample) |
| WO (1) | WO2010014895A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5976548B2 (ja) * | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療 |
| US10081542B2 (en) | 2010-04-20 | 2018-09-25 | University of Florida Research Foundation, lnc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| ES2770575T3 (es) | 2010-10-28 | 2020-07-02 | Pacira Pharmaceuticals Inc | Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo |
| US8709466B2 (en) | 2011-03-31 | 2014-04-29 | International Business Machines Corporation | Cationic polymers for antimicrobial applications and delivery of bioactive materials |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9374747B2 (en) * | 2012-11-02 | 2016-06-21 | Telefonaktiebolaget Lm Ericsson (Publ) | Network node, user node and methods for channel estimation |
| WO2014106856A1 (en) * | 2013-01-03 | 2014-07-10 | Council Of Scientific & Industrial Research | Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| DK3019619T3 (da) * | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
| TW201521762A (zh) | 2013-08-14 | 2015-06-16 | Univ Florida | 奈米酶、製備奈米酶的方法、以及使用奈米酶的方法 |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
| WO2016011222A2 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| US12109274B2 (en) | 2015-09-17 | 2024-10-08 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| CN112587504B (zh) * | 2016-10-17 | 2022-10-18 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| EP3541815A4 (en) | 2016-11-18 | 2020-07-15 | Pacira Pharmaceuticals, Inc. | ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME |
| CA3071968A1 (en) | 2017-08-04 | 2019-02-07 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
| EP3740241A1 (en) * | 2018-01-18 | 2020-11-25 | eTheRNA Immunotherapies NV | Lipid nanoparticles |
| KR20210093232A (ko) | 2018-10-09 | 2021-07-27 | 더 유니버시티 오브 브리티시 콜롬비아 | 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법 |
| CN109549934B (zh) * | 2018-12-25 | 2021-03-09 | 上海交通大学 | 一种多糖基脂质纳米粒子的制备方法 |
| JP2024521887A (ja) * | 2021-06-01 | 2024-06-04 | ナノベーション・セラピューティクス・インコーポレイテッド | 脂質ナノ粒子を用いるdnaベクター送達 |
| EP4248949B1 (en) | 2022-03-21 | 2024-08-28 | R.G.C.C. Holdings AG | Liposomal compositions |
| CA3255112A1 (en) | 2022-03-23 | 2023-09-28 | Nanovation Therapeutics Inc | HIGH STEROL LIPID NANOPARTICLES |
| CA3255116A1 (en) | 2022-04-01 | 2023-10-05 | Nanovation Therapeutics Inc | METHOD FOR ADMINISTRATING RNA AND ASSOCIATED COMPOSITION |
| KR20250057825A (ko) * | 2022-10-18 | 2025-04-29 | 가부시키가이샤 칩톤 | 테일러 반응 장치 및 캡슐 입자의 제조 방법 |
| WO2025021083A1 (en) * | 2023-07-24 | 2025-01-30 | National Institute Of Biological Sciences, Beijing | Lipid nanoparticle compositions for localized treatment of skin diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US20010007771A1 (en) * | 1996-05-29 | 2001-07-12 | Sean M. Sullivan | Cationic polymers and lipids for the delivery of nucleic acids |
| DE69841002D1 (de) * | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6841537B1 (en) * | 1998-04-22 | 2005-01-11 | Protiva Biotherapeutics Inc. | Combination therapy using nucleic acids and conventional drugs |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20080207542A1 (en) * | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007086883A2 (en) * | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7919466B2 (en) * | 2006-02-01 | 2011-04-05 | The Regents Of The University Of California | Lymphatic zip codes in tumors and pre-malignant lesions |
| US20070293449A1 (en) * | 2006-06-20 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for delivery of double-stranded rna |
| EP2076257A4 (en) * | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS |
-
2009
- 2009-07-31 WO PCT/US2009/052396 patent/WO2010014895A2/en not_active Ceased
- 2009-07-31 EP EP09803646.0A patent/EP2304026A4/en not_active Withdrawn
- 2009-07-31 US US13/003,816 patent/US20110111044A1/en not_active Abandoned
- 2009-07-31 CA CA2731173A patent/CA2731173A1/en not_active Abandoned
- 2009-07-31 JP JP2011521353A patent/JP2011529912A/ja active Pending
- 2009-07-31 TW TW098125813A patent/TW201004658A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529912A5 (enExample) | ||
| JP2011520983A5 (enExample) | ||
| JP5795072B2 (ja) | Rna干渉を誘導する核酸分子及びその用途 | |
| JP2012509258A5 (enExample) | ||
| EP2796150B1 (en) | Novel oligonucleotide conjugates and use thereof | |
| US9006191B2 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| KR101752812B1 (ko) | 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법 | |
| JP2012509272A5 (enExample) | ||
| JP2012509366A5 (enExample) | ||
| JP2012509273A5 (enExample) | ||
| ES2809481T3 (es) | Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma | |
| JP2015518373A5 (enExample) | ||
| JP2014530602A (ja) | アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法 | |
| JP2015502365A5 (enExample) | ||
| JP2011509258A5 (enExample) | ||
| WO2015082080A1 (en) | Means for lung specific delivery | |
| Bhavsar et al. | Translational siRNA therapeutics using liposomal carriers: prospects & challenges | |
| JP2023539341A (ja) | Dux4阻害剤およびその使用方法 | |
| US20130172405A1 (en) | Compositions and methods for silencing smad4 | |
| KR102701681B1 (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 | |
| CN120077134A (zh) | 靶向apoc3的多核酸分子及其用途 | |
| CN107630015B (zh) | 一种稳定的dna-rna双链结构 | |
| WO2023168202A2 (en) | Certain dux4 inhibitors and methods of use thereof | |
| JP2025540278A (ja) | 修飾免疫調節薬 | |
| AU2013202970A1 (en) | Silencing of polo-like kinase expression using interfering RNA |